Nalorphine
Sign in to saveNalorphine (; also known as '''N-allylnormorphine; brand names Lethidrone and Nalline''') is a mixed opioid agonist–antagonist with opioid antagonist and analgesic properties. It was introduced in 1954 and was used as an antidote to reverse opioid overdose and in a challenge test to determine opioid dependence.
Research
1,348 papers- Pharmacological characterization of nalorphine, a kappa 3 analgesic.The Journal of pharmacology and experimental therapeutics · 1991
- Nalorphine in opiate poisoning.British medical journal · 1969
- [Nalorphine; a summary].Die Pharmazie · 1956
- Letter: Neonatal-strength ampoules of nalorphine.British medical journal · 1976
- ON ANTIDOTES.British journal of anaesthesia · 1954
via PubMed
~2 min read
Encyclopedic overview
7 sectionsContents
- Pharmacology
- Pharmacodynamics
- Chemistry
- Analogues
- Synthesis
- See also
- References
Nalorphine (; also known as '''N-allylnormorphine; brand names Lethidrone and Nalline') is a mixed opioid agonist–antagonist with opioid antagonist and analgesic properties. It was introduced in 1954 and was used as an antidote to reverse opioid overdose and in a challenge test to determine opioid dependence.
Nalorphine was the second opioid antagonist to be introduced, preceded by nalodeine (N''-allylnorcodeine) in 1915 and followed by naloxone in 1960 and naltrexone in 1963. Due to potent activation of the κ-opioid receptor, nalorphine produces side effects such as dysphoria, anxiety, confusion, and hallucinations, and for this reason, is no longer used medically.
Excerpted from Wikipedia’s “Nalorphine” article, available under the CC BY-SA 4.0 licence.